Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Bio-Techne and Regulus collaborate in biomarker development » 07:10
12/02/20
12/02
07:10
12/02/20
07:10
TECH

Bio-Techne

$304.70 /

+1.34 (+0.44%)

, RGLS

Regulus

$0.70 /

+0.0649 (+10.22%)

Bio-Techne (TECH) and…

Bio-Techne (TECH) and Regulus Therapeutics (RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease treatment. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing. RGLS4326 is a first in class anti-miR-17 therapy currently in Phase 1b clinical development in ADPKD patients. This study will evaluate RGLS4326 for safety, pharmacokinetics, and pharmacodynamic effects on the levels of polycystin 1 and polycystin 2. This study is designed to assess whether different dose levels of RGLS4326 can increase levels of PC1 and PC2 in ADPKD patients. Regulus has elected to collaborate with Bio-Techne for the development of high-performance biomarker assays to support the assessment of PC1 and PC2 levels using the fully automated Simple Western instrument as a read-out. The Company anticipates availability of results from the first cohort by the end of Q1 2021.

ShowHide Related Items >><<
TECH Bio-Techne
$304.70 /

+1.34 (+0.44%)

RGLS Regulus
$0.70 /

+0.0649 (+10.22%)

TECH Bio-Techne
$304.70 /

+1.34 (+0.44%)

11/09/20 KeyBanc
Bio-Techne initiated with a Sector Weight at KeyBanc
11/06/20 Baird
Bio-Techne price target raised to $320 from $289 at Baird
09/30/20 Atlantic Equities
Bio-Techne initiated with an Overweight at Atlantic Equities
08/05/20 SVB Leerink
Bio-Techne price target raised to $285 from $265 at SVB Leerink
RGLS Regulus
$0.70 /

+0.0649 (+10.22%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
TECH Bio-Techne
$304.70 /

+1.34 (+0.44%)

RGLS Regulus
$0.70 /

+0.0649 (+10.22%)

Tuesday
Syndicate
Regulus announces $19.4M private placement of equity » 08:37
12/01/20
12/01
08:37
12/01/20
08:37
RGLS

Regulus

$0.64 /

+0.0005 (+0.08%)

Regulus Therapeutics…

Regulus Therapeutics announced that it has entered into a definitive securities purchase agreement in connection with a private placement to existing institutional and other accredited investors as well as new institutional investors. Upon the closing of the financing, which is anticipated to occur on December 3, the company expects to receive gross proceeds of approximately $19.4M, not including any proceeds that may be received upon exercise of warrants. The closing of the financing is subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the financing.

ShowHide Related Items >><<
RGLS Regulus
$0.64 /

+0.0005 (+0.08%)

RGLS Regulus
$0.64 /

+0.0005 (+0.08%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
RGLS Regulus
$0.64 /

+0.0005 (+0.08%)

Over a week ago
Earnings
Regulus reports Q3 EPS (4c), consensus (21c) » 17:46
11/05/20
11/05
17:46
11/05/20
17:46
RGLS

Regulus

$0.49 /

+0.0087 (+1.79%)

Reports Q3 revenue $5.0M…

Reports Q3 revenue $5.0M vs. $0.1M a year ago. "We are pleased with the progress on our ADPKD program with the recent announcement of dosing of the first patient in the Phase 1b clinical trial of RGLS4326 in patients with ADPKD", stated CEO Jay Hagan. "Next year is shaping up to be an important one for Regulus, with data from the first cohort anticipated by end of Q1 2021. We also achieved $10M in milestones from our collaboration with Sanofi enabling us to reduce our outstanding debt to $4.7M and extend the interest-only period through the end of 2021."

ShowHide Related Items >><<
RGLS Regulus
$0.49 /

+0.0087 (+1.79%)

RGLS Regulus
$0.49 /

+0.0087 (+1.79%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
RGLS Regulus
$0.49 /

+0.0087 (+1.79%)

Over a month ago
Hot Stocks
Regulus achieves interim enrollment milestone under collaboration with Sanofi » 08:10
11/02/20
11/02
08:10
11/02/20
08:10
RGLS

Regulus

$0.47 /

-0.0081 (-1.69%)

, SNY

Sanofi

$45.26 /

-0.38 (-0.83%)

Regulus Therapeutics…

Regulus Therapeutics (RGLS) announced that it has achieved the remaining $5M milestone associated with interim enrollment under its Collaboration and License Agreement with Sanofi (SNY) for its development of miR-21 programs. The Milestone was triggered upon achievement of an enrollment metric by Sanofi in its Phase 2 clinical study evaluating RG-012 for the treatment of patients with Alport Syndrome. The proceeds from this Milestone will be used to pay down the company's term loan with Oxford LLC. The payment to Oxford will reduce the remaining principal due under the term loan to approximately $4.7M and enable the company to receive an extension of interest-only payments through 2021, an extension of seven months from the previous terms. Under the terms of the Collaboration and License Agreement, the company is also eligible to receive an additional $25M upon the successful achievement of a development milestone anticipated in 2023 related to the ongoing Phase 2 HERA study.

ShowHide Related Items >><<
SNY Sanofi
$45.26 /

-0.38 (-0.83%)

RGLS Regulus
$0.47 /

-0.0081 (-1.69%)

RGLS Regulus
$0.47 /

-0.0081 (-1.69%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
SNY Sanofi
$45.26 /

-0.38 (-0.83%)

10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
SNY Sanofi
$45.26 /

-0.38 (-0.83%)

RGLS Regulus
$0.47 /

-0.0081 (-1.69%)

SNY Sanofi
$45.26 /

-0.38 (-0.83%)

SNY Sanofi
$45.26 /

-0.38 (-0.83%)

Conference/Events
Regulus management to meet virtually with Wedbush » 04:55
10/29/20
10/29
04:55
10/29/20
04:55
RGLS

Regulus

$0.50 /

-0.0142 (-2.77%)

Virtual Meeting to be…

Virtual Meeting to be held on October 29 hosted by Wedbush.

ShowHide Related Items >><<
RGLS Regulus
$0.50 /

-0.0142 (-2.77%)

RGLS Regulus
$0.50 /

-0.0142 (-2.77%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
RGLS Regulus
$0.50 /

-0.0142 (-2.77%)

Conference/Events
Regulus management to meet virtually with Wedbush » 11:03
10/26/20
10/26
11:03
10/26/20
11:03
RGLS

Regulus

$0.53 /

-0.012 (-2.20%)

Virtual Meeting to be…

Virtual Meeting to be held on October 29 hosted by Wedbush.

ShowHide Related Items >><<
RGLS Regulus
$0.53 /

-0.012 (-2.20%)

RGLS Regulus
$0.53 /

-0.012 (-2.20%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
RGLS Regulus
$0.53 /

-0.012 (-2.20%)

Hot Stocks
Regulus: First patient dosed in Phase 1b clinical trial of RGLS4326 » 08:09
10/15/20
10/15
08:09
10/15/20
08:09
RGLS

Regulus

$0.55 /

-0.0045 (-0.82%)

Regulus Therapeutics…

Regulus Therapeutics announced initiation of dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD. The first cohort is expected to enroll up to nine patients who will receive RGLS4326 every two weeks over a six week period. The company anticipates availability of results from the first cohort by the end of Q1 2021.

ShowHide Related Items >><<
RGLS Regulus
$0.55 /

-0.0045 (-0.82%)

RGLS Regulus
$0.55 /

-0.0045 (-0.82%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
RGLS Regulus
$0.55 /

-0.0045 (-0.82%)

Hot Stocks
Regulus receives $5M milestone payment from Sanofi » 08:10
10/13/20
10/13
08:10
10/13/20
08:10
RGLS

Regulus

$0.52 /

-0.03 (-5.45%)

, SNY

Sanofi

$51.08 /

+0.34 (+0.67%)

Regulus Therapeutics…

Regulus Therapeutics announced receipt of a total of $5M in milestone and material payments from Sanofi (SNY). As outlined in the recent amendment to the Company's term loan agreement with Oxford, the Company utilized the proceeds to pay down $5M in principal outstanding, reducing the remaining principal due under the term loan to approximately $9.6M. In August, the Company entered into an amendment with Sanofi concerning the receipt of potential milestones from Sanofi for its development of miR-21 programs. Under the terms of the amendment with Sanofi, the Company was eligible to receive $4M upon the completion of transfer and verification of certain materials valued at an additional $1M sold to Sanofi. In addition to this payment of $5M received, the Company is eligible to receive an additional $5M upon achievement of the interim enrollment milestone and $25M upon the achievement of the development milestone. Concurrently with this recent Sanofi amendment, the Company announced an amendment of its term loan agreement with Oxford, under which the Company is eligible for up to an additional seven months of interest only payments in the event the Company pays down an additional $5M in loan principal before April 30, 2021.

ShowHide Related Items >><<
SNY Sanofi
$51.08 /

+0.34 (+0.67%)

RGLS Regulus
$0.52 /

-0.03 (-5.45%)

RGLS Regulus
$0.52 /

-0.03 (-5.45%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
SNY Sanofi
$51.08 /

+0.34 (+0.67%)

10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
SNY Sanofi
$51.08 /

+0.34 (+0.67%)

RGLS Regulus
$0.52 /

-0.03 (-5.45%)

SNY Sanofi
$51.08 /

+0.34 (+0.67%)

SNY Sanofi
$51.08 /

+0.34 (+0.67%)

SNY Sanofi
$51.08 /

+0.34 (+0.67%)

Over a quarter ago
Hot Stocks
Regulus restructures Sanofi, Oxford loan agreements » 08:10
08/31/20
08/31
08:10
08/31/20
08:10
RGLS

Regulus

$0.57 /

+0.0123 (+2.21%)

, SNY

Sanofi

$50.20 /

-0.58 (-1.14%)

Regulus Therapeutics…

Regulus Therapeutics announced that pursuant to an amendment of its term loan agreement with Oxford LLC, the company is eligible for up to an additional seven months of interest only payments in the event the company pays down $10M in loan principal before April 30, 2021 utilizing proceeds from the sale of materials to, and potential milestones received from, Sanofi (SNY). In the event the Principal Paydown Event does not occur by April 30, 2021, the company will make principal and accrued interest payments, in arrears, commencing May 1, 2021, in accordance with the previously amended terms. If the Principal Paydown Event occurs after April 30, 2021 but on or before July 31, 2021, then the company will recommence an extended interest only payment period through December 31, 2021. In the event the company receives the additional interest only period, principal and accrued interest payments will recommence on January 1, 2022.

ShowHide Related Items >><<
SNY Sanofi
$50.20 /

-0.58 (-1.14%)

RGLS Regulus
$0.57 /

+0.0123 (+2.21%)

RGLS Regulus
$0.57 /

+0.0123 (+2.21%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
09/06/19 H.C. Wainwright
Regulus initiated with a Buy at H.C. Wainwright
SNY Sanofi
$50.20 /

-0.58 (-1.14%)

08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/19/20 Stifel
Principia Biopharma downgraded to Hold from Buy at Stifel
08/18/20 SVB Leerink
Principia Biopharma downgraded to Market Perform at SVB Leerink
08/18/20 Baird
Principia Biopharma price target raised to $100 from $78 at Baird
SNY Sanofi
$50.20 /

-0.58 (-1.14%)

RGLS Regulus
$0.57 /

+0.0123 (+2.21%)

SNY Sanofi
$50.20 /

-0.58 (-1.14%)

SNY Sanofi
$50.20 /

-0.58 (-1.14%)

SNY Sanofi
$50.20 /

-0.58 (-1.14%)

Earnings
Regulus reports Q2 EPS (23c), consensus (11c) » 16:14
08/13/20
08/13
16:14
08/13/20
16:14
RGLS

Regulus

$0.63 /

-0.0426 (-6.32%)

Reports Q2 revenue $0,…

Reports Q2 revenue $0, consensus $3.34M. "We are pleased with the progress of our ADPKD program and the completion of dosing of the MAD clinical study for RGLS4326 in healthy volunteers," said CEO Jay Hagan. "We plan to initiate a Phase 1b study in patients with ADPKD to evaluate short-term treatment of RGLS4326 for safety, tolerability, pharmacokinetics, and changes in biomarkers of the disease. We have also recently completed additional non-clinical studies needed to address some of the FDA requirements to support studies of extended duration."

ShowHide Related Items >><<
RGLS Regulus
$0.63 /

-0.0426 (-6.32%)

RGLS Regulus
$0.63 /

-0.0426 (-6.32%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
09/06/19 H.C. Wainwright
Regulus initiated with a Buy at H.C. Wainwright
RGLS Regulus
$0.63 /

-0.0426 (-6.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.